Thus, new targets are being studied for the treatment of osteoporosis, such as cathepsin K inhibitors or anti-sclerostin therapies; however, an ideal osteoporosis therapy has not yet been developed, as they still present considerable adverse effects that limit their long-term use. The gene discussed is SOST; the disease is osteoporosis.